Search clinical trials for: Insulin+NPH

Total 3654 results

Geropharm

Completed

Efficacy and Safety of Insulin Rinsulin® NPH Compared to Humulin® NPH in Type 2 Diabetes Mellitus Patients

Diabetes Mellitus, Type 2

Russian Federation
Geropharm

Completed

Comparative Study of Rinsulin® NPH, Suspension for Subcutaneous Administration, 100 IU/ml (GEROPHARM LLC, Russia) and Humulin® NPH, Suspension for Subcutaneous Administration, 100 IU/ml (Lilly France, France) Using the Euglycemic Hyperinsulinemic Clamp Method

Pharmacokinetics | Bioequivalence

Russian Federation
Emory University
Sanofi

Completed

Basal Insulin in the Management of Patients With Diabetic Ketoacidosis (DKA)

Diabetic Ketoacidosis

United States
ikfe-CRO GmbH
IKFE Institute for Clinical Research and Development

Unknown

Establishing Cardiovascular Biomarkers to Define Preferred Lantus® Use

Insulin-requiring Type 2 Diabetes Mellitus

Germany
Providence Health & Services

Withdrawn

Comparison Study of Insulin Glargine and NPH Insulin

Diabetes

United States
Hennepin Healthcare Research Institute
Eli Lilly and Company

Completed

Inpatient Diabetes on Corticosteroids

Diabetes Mellitus

United States
University of Aarhus

Completed

Effect of NPH Insulin, Insulin Detemir and Insulin Glargine on GH-IGF-IGFBP Axis

Diabetes Mellitus, Type 1

Denmark
Biologics & Biosimilars Collective Intelligence...
Merck Sharp & Dohme LLC; Pfizer; AbbVie; University of Pittsburgh; Boehringer Ingelheim and other collaborators

Completed

Descriptive Analysis of Long- and Intermediate-Acting Insulin in Adult Diabetics

Diabetes
Universidad de Guanajuato

Completed

Insulin Schemes for Type 2 Diabetes Control

Type 2 Diabetes Mellitus

Mexico
Novo Nordisk A/S

Completed

Basal Bolus of Insulin Aspart Including Insulin NPH and Biphasic Insulin Aspart in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany, Poland, Russian Federation, Spain, Sweden, Netherlands, Singapore, Malaysia, France, Croatia, Romania, United Kingdom, Hong Kong
St. Luke's-Roosevelt Hospital Center

Completed

Glycemic Control Using Insulin Levemir Versus Insulin NPH for Diabetes in Pregnancy

Diabetes, Gestational | Diabetes, Type 2

United States
Sanofi

Completed

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulins in Insulin Naïve Patients Initiating Insulin (Reach-Control)

Diabetes Mellitus, Type 2

Germany, Spain, Brazil, France, Ireland, Romania, United Kingdom
Sanofi

Completed

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulin in Patients Already Using Basal Insulin (REGAIN CONTROL)

Diabetes Mellitus, Type 2

Italy, Ireland, Spain, Greece, Finland, Romania, Brazil, United Kingdom, France, Switzerland
Charles Drew University of Medicine and Science
National Center for Research Resources (NCRR)

Terminated

Insulin Glargine Versus Twice-Daily NPH

Type 2 Diabetes Mellitus

United States
Novo Nordisk A/S

Completed

Observational Study to Evaluate Safety and Efficacy of Insulin Therapy in Type 2 Diabetes Mellitus Subjects Failing on Oral Anti-diabetic Agents

Diabetes Mellitus, Type 2 | Diabetes

Indonesia
Ain Shams University

Unknown

Intermediate and Long Acting Insulin Young Children Type 1 Diabetes.

Type 1 Diabetes Mellitus With Hypoglycemia | type1diabetes

Egypt
Yaounde Central Hospital

Completed

Impact of a Diabetes Camp on Glycemic Control Among Children and Adolescents Living With Type 1 Diabetes in Cameroon

Type 1 Diabetes
Karolinska Institutet

Unknown

Basal Analog Study - Comparison of Lantus or Levemir With NPH Insulin From T1DM Diagnosis (BAS)

Diabetes Mellitus Type 1

Sweden
Novo Nordisk A/S

Completed

Effect of Insulin Detemir on Blood Glucose Control in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

China
Novo Nordisk A/S

Completed

Comparison of Insulin Detemir Morning, Insulin Detemir Evening and NPH Insulin Evening in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Denmark, Spain, Norway, Italy, France, Netherlands
Novo Nordisk A/S

Terminated

Comparison of Insulin Detemir and NPH Insulin Given Once Daily in Ageing Subjects With Type 2 Diabetes (3L)

Diabetes Mellitus, Type 2 | Diabetes

United Kingdom, France
Novo Nordisk A/S

Completed

Comparison of Insulin Detemir and NPH With Respect to Lowering the Blood Sugar and Symptoms Experienced by Type 1 Diabetics During Hypoglycaemia

Diabetes | Diabetes Mellitus, Type 1

United Kingdom
Novo Nordisk A/S

Completed

Efficacy and Safety of Insulin Detemir in Type 2 Diabetes Inadequately Controlled on OHA Therapy Alone

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Observational Study of Patients Using Levemir® or Insulatard® as Start Insulin for Treatment of Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Slovenia
Novo Nordisk A/S

Completed

Self-control Trial to Evaluate the Remission Rate in Newly Diagnosed Type 2 Diabetes Patients After Treatment With Insulin Aspart

Diabetes Mellitus, Type 2 | Diabetes

China
University of Giessen
Sanofi

Completed

Comparison of Insulin Glargine and NPH Insulin at Night and at Hypoglycemia in Type 2 Diabetes (ClampHOE901)

Diabetes

Germany
Novo Nordisk A/S

Completed

Efficacy and Safety of Repaglinide Combined With Insulin NPH in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Malaysia, South Africa, Hong Kong, Taiwan, Philippines
Sanofi

Completed

Health Assessment, Patient Treatment Satisfaction and Quality-of-Life in Insulin-Naive Type 2 Diabetes Patients

Diabetes Mellitus, Type 2

Germany
Novo Nordisk A/S

Completed

Examining the Long-term Safety of Insulin Aspart When Used as a Part of the Treatment for Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Russian Federation, Israel, Croatia, Czech Republic, Slovenia
Novo Nordisk A/S

Completed

Pharmacokinetics of Insulin Detemir in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States
Novo Nordisk A/S

Completed

Safety and Efficacy of Insulin Detemir in Combination With OAD in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Poland, Russian Federation, Denmark, Sweden, Macedonia, The Former Yugoslav Republic of, Norway, Croatia, France, Belgium, Slovakia
National Institute of Neurosciences and Hospital...

Completed

Insulin for Hyperglycemia in Stroke Trial

Hyperglycemia | Stroke, Acute

Bangladesh
Novo Nordisk A/S

Completed

Pharmacokinetics of Insulin Detemir in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

Human Insulin NPH and Insulin Aspart in Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Argentina
Novo Nordisk A/S

Completed

Safety and Efficacy of Insulin Aspart vs. Regular Human Insulin in Gestational Diabetes

Diabetes | Gestational Diabetes

United States
Novo Nordisk A/S

Completed

Pharmacodynamics and Pharmacokinetics of Insulin Detemir in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

Observational Study of Type 2 Diabetes Patients Failing on Oral Anti-diabetic Agents Initiated on Levemir® or Insulatard® (EVIDENCE)

Diabetes Mellitus, Type 2 | Diabetes

Romania
Sanofi

Completed

Effect of Insulin Glargine in Insulin Naïve Subjects With Type 2 Diabetes on Oral Hypoglycemic Agent(s)

Diabetes Mellitus, Type 2

United States, Canada
Novo Nordisk A/S

Completed

Comparison of NPH Insulin and Insulin Detemir in Children and Adolescents With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

France, Denmark, Finland, Russian Federation, Macedonia, The Former Yugoslav Republic of, Hungary, Bulgaria, United Kingdom, Turkey, Poland, Czech Republic
Novo Nordisk A/S

Completed

Evaluation of the Efficacy and Safety of Insulin Detemir Compared With That of NPH Insulin in Subjects With Type 1 Diabetes.

Diabetes Mellitus, Type 1

United Kingdom, Denmark, Sweden, Netherlands, Belgium, Finland, France, Australia, Ireland, Norway
Novo Nordisk A/S

Completed

Safety of Insulin Detemir in Children With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

Efficacy and the Safety of Insulin Detemir in Subjects With Insulin Requiring Diabetes

Diabetes | Diabetes Mellitus, Type 1

Japan
Tehran University of Medical Sciences

Completed

Cost Effectiveness of Glargine Insulin Versus NPH Insulin

Type 2 Diabetes Mellitus

Iran, Islamic Republic of
Novo Nordisk A/S

Completed

Long Term Safety Trial to Compare Insulin Treatment With Preprandial Inhaled Human Insulin to s.c. Insulin Aspart Both Combined With NPH in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Australia
Novo Nordisk A/S

Completed

Efficacy and Safety of Insulin Aspart in Subjects With Type 1 or Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

China
Jing Luo
The Leona M. and Harry B. Helmsley Charitable Trust

Active, not recruiting

Human Versus Analogue Insulin for Youth With Type 1 Diabetes in Low-Resource Settings (HumAn-1)

Diabetes Mellitus, Type 1 | Type 1 Diabetes

Tanzania, Bangladesh
King Edward Medical University

Completed

Comparison of Insulin Glargine and Regular Insulin Versus NPH and Regular Insulin in the Treatment of T1DM

To Assess the Glycemic Control of Insulin Glargine in Combination With Regular Insulin in Type 1 Diabetes in Children

Pakistan
Hadassah Medical Organization

Unknown

Insulin Loaded Orally Dissolved Films (Insulin-ODF)

Healthy Volunteers
Novo Nordisk A/S

Completed

Efficacy and Safety of Insulin Detemir Versus Neutral Protamine Hagedorn (NPH) Insulin in Pregnant Women With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Israel, Poland, United Kingdom, Denmark, Spain, France, Austria, Norway, Russian Federation, Canada, Croatia, Argentina, South Africa, Australia, Ireland, Brazil, Finland
Amsterdam UMC, location VUmc

Completed

Insulin Detemir Action in Cerebro (INcEREBRO)

Type 1 Diabetes

Netherlands

Search clinical trials for: Insulin+NPH

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Oman

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations